Sarepta Therapeutics Inc
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →
Analyst Sentiment
Sarepta Therapeutics faces potential headwinds at current valuations. Our analysis suggests 35.2% downside risk to our $13.28 target. Investors may want to consider reducing exposure or waiting for a better entry point.
The 24/7 Factor
5-Year Projection
Prediction History
| Date | Price Target | Stock Price | Rating | Upside |
|---|---|---|---|---|
| $12.90 | $18.79 | SELL | −31.3% | |
| $12.68 | $18.10 | SELL | −29.9% | |
| $12.28 | $16.78 | SELL | −26.8% | |
| $16.52 | $14.86 | BUY | +11.1% | |
| $17.17 | $15.88 | BUY | +8.1% | |
| $16.97 | $17.23 | HOLD | −1.5% |
Frequently Asked Questions
What is the SRPT stock price prediction for 2030?
Looking ahead to 2030, our model projects SRPT could trade at an average price of $10.93, with a potential range between $8.20 and $13.66. This represents a potential 46.7% decline from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.
Is SRPT a buy, sell, or hold right now?
24/7 Wall St. currently rates SRPT as a SELL. Significant downside (-35.2%) Among Wall Street analysts, 8 rate it Buy, 11 rate it Hold, and 5 rate it Sell.
What is the SRPT stock price target in an optimistic scenario?
Our optimistic scenario for SRPT projects a price of $18.14 over the next 12 months. Even under favorable conditions, this suggests limited upside from today’s price of $20.51, indicating the stock may currently be trading near or above fair value.
What is the downside risk for SRPT stock?
In our conservative scenario, SRPT could trade as low as $12.25 over the next 12 months, representing a 40.3% decline from current levels. This scenario accounts for potential headwinds including earnings misses, competitive pressures, or broader market weakness.
Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →